Vesicular stomatitis virus (VSV) is a candidate for development for cancer therapy. We created a recombinant replicating VSV (rrVSV) with an altered surface protein that targeted preferentially to breast cancer cells. The rrVSV genome contained a single glycoprotein (gp) gene derived from Sindbis virus. This gene expressed a chimeric Sindbis E2 binding gp and the native Sindbis E1 fusion gp. The chimeric E2 binding gp, called Sindbis-SCA-erbb2, was modified to reduce its native binding function and to contain a single chain antibody (SCA) with specificity for the human epidermal growth factor receptor Her2/neu protein, erbb2. These viruses selectively infected, replicated in and killed cells expressing erbb2. The titer of rrVSV on SKBR3 cells, a human breast cancer cell line which highly expresses erbb2 was 3.1 Â 10 7 /ml compared with a titer of 7.3 Â 10 5 /ml on 143 cells, a human osteosarcoma cell line which does not express erbb2. The titer of rrVSV on D2F2/E2 cells, a mouse mammary cancer cell line stably transfected to express human erbb2 was 2.46 Â 10 6 /ml compared with a titer of 5 Â 10 4 /ml on the parent D2F2 cells which do not express erbb2. When titered on erbb2-negative cells, non-replicating pseudotype VSV coated with Sindbis-SCA-erbb2 had b3% the titer of pseudotype VSV coated with wild type Sindbis gp indicating that the chimeric Sindbis gp had severely impaired binding to the natural receptor. Analysis of the protein composition of the rrVSV found low expression of the modified Sindbis gp on the virus. D
Introduction
Viruses and viral vectors that kill specific cells are being designed for cancer therapy (Ring, 2002; Russell, 1994; Wildner, 2001; Zwiebel, 2001) . Important issues are safety, efficacy, and targeting. VSV is an excellent candidate for development as an oncolytic virus because it is an efficient cell killer that grows and spreads rapidly and yet is safe for human use (de Mattos et al., 2001) . VSV is endemic in certain human populations but is not pathogenic. Wild type (wt) VSV has eradicated established tumors in mice when injected intratumorally or intravenously (Balachandran et al., 2001; Fernandez et al., 2002) . Selectivity was based on the absence of an interferon response in the tumor cells (Stojdl et al., 2000) . Safety could be further improved by restricting the tropism of the virus.
Our goal in the present study was to create a VSV that directly targeted to Her2/neu over-expressing breast cancer cells. The Her2/neu receptor is an excellent target because it is over-expressed in 25-30% of human breast cancers and is a critical contributor to an aggressive tumor phenotype . VSV is an enveloped negative strand RNA virus with a single surface glycoprotein (gp) called G that fully determines binding of the virus as well as promoting pH-dependent fusion of the virus envelope with endosome membranes (Rose and Whitt, 2001) . The receptor for G is ubiquitous and VSV promiscuously infects most cell types. We eliminated the G gene from the VSV genome and substituted a gene coding for a modified Sindbis virus (SV) gp. The surface gp of SV consists of an E1 fusion protein and an E2 binding protein. Deletion of amino acids 72 and 73 within E2 reduces binding and infectivity of the virus N90% (Dubuisson and Rice, 1993) . The Sindbis gp gene was further modified at this site to encode two synthetic immunoglobulin G (IgG) Fc-binding domains called ZZ derived from protein A of the Staphylococcus aureus spa gene (Ohno et al., 1997; Morizono et al., 2001; Sawai and Meruelo, 1998) . Sindbis viruses and retroviruses expressing this ZZ-modified gp could be targeted to specific cells by the addition of antibody. Genetic engineering has previously been developed to create VSV from plasmid components (Schnell et al., 1997) . We have used this technology to create an rrVSV expressing the ZZ-modified Sindbis gp (Bergman et al., 2003) . This virus was selectively targeted to Her2/neu amplified human breast cancer in the presence of monoclonal antibodies directed to the Her2/neu receptor. However, the potential use of this virus in the clinic is limited because the titers were low and because targeting required that a specific antibody attach to a non-specific antibody combining site on the viral surface. In vivo competition for this non-specific site will include the large pool of host IgG antibodies. In addition, selective adaptation of this virus on targeted cells was difficult because each new generation of virus required additional antibody to allow binding and infection of the next round of cells. We therefore created a new chimeric SV gp gene, called Sindbis-SCA-erbb2, by removing the gene segment encoding ZZ and substituting a gene segment encoding for a single chain antibody (SCA) directed to erbb2. Initially, we synthesized non-replicating pseudotype VSV whose surface gp was supplied in trans by a plasmid expressing the Sindbis-SCA-erbbB2 and demonstrated selective infection of Her2/neu expressing cancer cells. We confirmed that this modification of the Sindbis E1 gp reduced non-specific binding N90% compared to wt Sindbis gp. We then substituted this gene within the VSV genome in place of the G gene and created replicating VSV whose only surface gp was Sindbis-SCA-erbb2. This rrVSV selectively infected Her2/neu expressing cancer cells.
Results
Non-replicating pseudotype VSV coated with Sindbis-SCA-erbb2 gp specifically infects Her2/neu over-expressing cells
Our goal was to develop VSV for clinical use in cancer therapy by restricting its tropism to cells that over-express the Her2/neu receptor. To this end, a recombinant VSV (rVSV) genome was constructed in which the G gene was replaced by a gene encoding green fluorescent protein (EGFP-DG/XN2). This construct was used to create a nonreplicating virus whose genome consisted of rVSV-EGFP-DG and whose surface protein, supplied in trans by transfection, was either Sindbis-SCA-erbb2 or wt Sindbis gp. Titers of these viruses were easily determined by infecting a target cell line and counting green cells 1 day later. Titers were determined on two pairs of cell lines, SKBR3 versus 143 cells and D2F2/E2 versus D2F2 cells. SKBR3 is a human breast cancer line that highly expresses Her2/neu and 143 is a human osteosarcoma cell line that does not express Her2/neu. D2F2/E2 is a mouse mammary cancer cell line that has been stably transfected with a plasmid expressing human Her2/neu and D2F2 is the parent cell line. Infection with pseudotype rVSV-EGFP-DG coated with wt Sindbis gp showed no specificity for Her2/neu expressing cells and yielded similar titers in both cell lines from each pair ( Fig. 1A) . On the other hand, pseudotype rVSV-EGFP-DG coated with Sindbis-SCA-erbb2 gp showed a greater than 10-fold better titer on the cell line in each pair that expressed Her2/neu ( Fig. 1B) . Incubation of the virus in the presence of Herceptin, an antibody directed to the erbb2 receptor on the cell surface, reduced titer on D2F2/E2, the cell line expressing erbb2 but had no effect on titer on D2F2, the parent cell line that did not express erbb2 (Fig. 2) . Inhibition was antibody dose-dependent and reached a maximum of 69% inhibition at an antibody concentration of 20 Ag/ml. An irrelevant antibody control had no effect. Inhibition by anti-erbb2 antibody may have been incomplete because, as suggested by others, the virus with multiple binding sites may have higher avidity for the receptor than the antibody (Martin et al., 2003) . Also these antibodies bind to the cellular receptor and not to the virus and are therefore not directly neutralizing for the virus. Titer of the pseudotype rVSV-EGFP-DG coated with Sindbis-SCA-erbB2 gp was higher on the SKBR3 cells than the D2F2/E2 cells. One possible explanation was that SKBR3 cells expressed higher amounts of erbb2 on the cell surface than D2F2/E2 cells, as demonstrated by flow cytometry. The mean fluorescence on cells stained with the humanized anti-erbb2 monoclonal antibody Herceptin was 401 on SKBR3 cells, 186 on D2F2/E2 cells, and 12 on D2F2 cells. When titered on erbb2-negative cells, nonreplicating pseudotype VSV coated with Sindbis-SCA-erbb2 had b3% the titer of pseudotype VSV coated with wild type Sindbis gp indicating that the chimeric Sindbis gp had severely impaired binding to the natural receptors ( Figs. 1A-B ). We have previously demonstrated that the baseline titer of control VSV-EGFP-DG created without a surface gp was very low (b10 3 /ml) and presumably represented residual inoculum virus used in the producer cells to create these various pseudotypes (Bergman et al., 2003) .
Replicating recombinant VSV (rrVSV) expressing
Sindbis-SCA-erbb2 specifically infects Her2/neu over-expressing cells Once we knew that Sindbis-SCA-erbbB2 gp targeted to the Her2/neu receptor, we constructed a recombinant VSV (rVSV) genome in which the G gene was replaced by a gene encoding Sindbis-SCA-erbb2 as well as a separate gene encoding green fluorescent protein (Sindbis-SCA-erbb2-EGFP-DG/XN2). A replication-competent VSV virus was created from this genome, which contained the gene expressing Sindbis-SCA-erbb2 in the viral genome and whose only coat proteins were the Sindbis derived E1 and Sindbis-SCA-erbb2 gp. This virus was called rrVSV-Sindbis-SCA-erbb2 and showed targeted infection of Her2/ neu expressing SKBR3 and D2F2/E2 cells (Fig. 3) . The titer of the rrVSV was N40-fold better on the cell line in each pair that expressed Her2/neu. Two color flow cytometric analysis demonstrated that when rrVSV expressing Sindbis-SCA-erbb2 was incubated with a mixed culture of SKBR3 and 143, 25% of the Her2/neu overexpressing SKBR3 were infected compared with 2.5% of the 143 cells ( Fig. 4 ). In addition to specific targeting, rrVSV-expressing Sindbis-SCA-erbb2 also displayed spe- cific replication ( Fig. 5 ) and killing in Her2/neu expressing cells. The cytopathic effect of rrVSV was measured in cells that did and did not express Her2/neu and based on trypan blue exclusion 1 day after infection at MOI = 0.5 was 92.1% in SKBR3 cells and 7.7% in 143 cells.
Stability and concentration of viral particles
In the future, clinical applications of this virus may require concentration and storage. rrVSV was reasonably stable to freeze/thaw. Two freeze/thaw cycles of the virus produced a 21% loss of titer for wt VSV and a 39% loss of titer for rrVSV expressing Sindbis-SCA-erbb2. rrVSV expressing Sindbis-SCA-erbb2 could be easily concentrated 40 fold by filtration (Centricon-Plus-20 Centrifugal Filter Device with Biomax membrane, 100 K NMWL, Millipore Corp., Billerica, MA). Further concentration was not attempted. Filtration concentrated the virus from 36 ml with a titer of 1.44 Â 10 6 /ml to 0.5 ml with a titer of 5.7 Â 10 7 /ml. Recovery rate was 55%.
Endosomal pH dependence
We sought to determine whether rrVSV with a new attachment protein would still enter its target cells via the endosome. Bafilomycin A1, a macrolide antibiotic, is a specific inhibitor of vacuolar-type H+-ATPase that blocks acidification of the endosome. Titers on Her2/neu overexpressing SKBR3 cells of pseudotype VSV coated with either wt VSV-G gp, wt Sindbis gp or recombinant Sindbis-SCA-erbb2 gp were determined in the presence of Bafilomycin, 30 nM. Bafilomycin blocked N99% of infection with all three viruses indicating that viral entry of the rrVSV was endosomal-dependent ( Fig. 6 ). We have previously shown that this concentration of Bafilomycin did not inhibit infectivity of a pseudotype VSV coated with the F and HN gp of SV5 virus which entered the cell by direct fusion with the cell membrane (Bergman et al., 2003) .
Protein composition of the recombinant viruses
We performed SDS-PAGE analysis of 35 S-methionine radiolabeled pseudotype and replicating recombinant viruses to confirm incorporation of the expected proteins into each virus. Fig. 7 demonstrates that all rrVSV contain the VSV proteins M, N, P, and L. The yield of pseudotype viruses is lower than rrVSV in part because we could achieve higher titers of replicating than pseudotype viruses (Figs. 1 and 3) and in part because the radiolabeling conditions required more extensive purification of the pseudotype than the replicating viruses. Nonetheless, all the VSV proteins except for P are clearly visible. Most importantly, the rrVSV contain the expected Sindbis E1 and modified Sindbis E2 gp and do not contain VSV G gp. Comparison of viruses expressing wt Sindbis E2, Sindbis E2 modified to express ZZ and Sindbis E2 modified to express SCA-erbb2 shows the expected higher migration of the E2 protein as larger inserts are added to the gene. Sindbis-ZZ adds 0.438 kb coding for two synthetic immunoglobulin G (IgG) Fcbinding domains, whereas Sindbis-SCA-erbb2 adds 0.867 kb coding for the SCA and linkers. The unmodified E1 band remains the same size in the three viruses. Protein analysis of the rrVSV demonstrates poor incorporation of modified Sindbis glycoprotein into the rrVSV particles compared with wt VSV particles (Fig. 7) . The difference in labeling intensity is not an artifact of amino acid composition because the number of methionine amino acids in VSV-G, Sindbis E1 and Sindbis E2 are similar. Possible explanations for the difference include variations in gp synthesis, transport or viral incorporation. Fig. 7 demonstrates that wt Sindbis and Sindbis-ZZ gp incorporation into virus were better when virus was prepared at 32 than 37 8C, suggesting a problem in protein transport. Incorporation of Sindbis-SCA-erbb2 was not temperature-dependent but was poor in the replicating virus and not visible in the pseudotype virus. A block in protein trafficking that is not relieved at lower temperature may explain the poor incorporation of Sindbis-SCA-erbb2. To examine modified Sindbis gp synthesis, we performed SDS-PAGE analysis of cell extracts prepared at various times following infection of D2F2/E2 cells with rrVSV expressing Sindbis-SCA-erbb2 (Fig. 8) . The modified E2 gp was synthesized appropriately, and as expected, there are two bands for the gp with the slightly larger band representing a precursor protein. Purified virus, as shown in Fig. 7 , contains only the lower band. Cell lysate from virus Fig. 7 . SDS-PAGE analysis of pseudotype and replicating recombinant viruses. Viruses were prepared in cells metabolically labeled with 35 S-methionine. wt VSV and rrVSV were grown in SKBR3 cells. Pseudotypes were made in BHK 21 cells. Each virus was prepared at either 32 8C (Lanes marked A) or 37 8C (Lanes marked B). The wt VSV proteins are used as molecular weight (MW) markers. VSV P protein migrates larger than its calculated MW because it is phosphorylated. The lanes contain the following viruses: (1) rrVSV expressing Sindbis-ZZ, a modified Sindbis gp with the addition of 0.438 kb coding for two synthetic immunoglobulin G (IgG) Fc-binding domains. (2) infected cells treated with monensin, GolgiStopk, 0.66 Al/ ml, (Cat. No. 2076KK, BD Biosciences) contains only the upper band because processing through the Golgi is interrupted (data not shown) (Sariola et al., 1995; Watson et al., 1991) .
Discussion
We have demonstrated the ability to create an autonomous replicating VSV virus that is targeted to specific cancer cells by a single chain antibody expressed on the viral surface. rrVSV were made whose genome possessed a gp gene that was a modified Sindbis gp cassette containing an SCA directed to erbb2. Sindbis gp was utilized because previous work had identified a site in which a new protein domain could be inserted that would be functional and also impair native Sindbis binding (Dubuisson and Rice, 1993; Ohno et al., 1997) . A similar site in the VSV G gene has not been discovered. This new rrVSV expressing Sindbis-SCA-erbb2 selectively infected cancer cells expressing the Her2/neu receptor protein achieving titers of 3.1 Â 10 7 /ml. Previous reports have used SCA to target retroviruses, adeno-associated virus (AAV) and attenuated measles virus (MV). For retroviruses and AAV, titers at best were only about 1 Â 10 5 /ml (Jiang et al., 1998; Khare et al., 2001; Marin et al., 1996; Martin et al., 2003; Yang et al., 1998) . The SCA gene was not incorporated into the retroviral genome and the viruses could not replicate. These viruses cannot be used directly to kill tumor cells because they are not cytolytic. For MV, the titers against specific cells were 6 Â 10 4 -6 Â 10 5 /ml and native MV binding was not at all attenuated. Rather, the tropism of the virus was extended to cells not normally infected by MV. Unlike retroviruses, however, these targeted MV were replication competent and cytolytic (Bucheit et al., 2003; Hammond et al., 2001; Peng et al., 2003) . The present rrVSV particle grew to titers of 10 7 /ml, was stable to freeze/thaw and could be concentrated. Cell entry was endosome-dependent. These findings are consistent with previous work, which demonstrated that VSV is able to form viable virus using foreign gp. Studies showed efficient budding of recombinant VSV expressing chimeric G proteins with the transmembrane and cytoplasmic domains derived from the human CD4 protein (Schnell et al., 1996) . A cytoplasmic domain of at least 9 amino acids was required but there was no requirement for a specific sequence in that domain (Schnell et al., 1998) .
Analysis of the protein composition of rrVSV demonstrated much lower concentration of gp than that found in wt VSV. Possible explanations for the difference include variations in gp synthesis, transport or viral incorporation. Sindbis-SCA-erbb2 gp is a synthetic chimeric protein with no natural counterpart that may not traffic easily through the cellular endoplasmic reticulum and Golgi apparatus to the plasma membrane and may not be efficiently incorporated into the viral envelope. Similar results have previously been reported for an SCA-retroviral surface protein chimera (Martin et al., 2003) . We intend to explore the reasons for poor incorporation in future work. Understanding this failure may suggest further modifications of the chimeric protein that will improve its ability to incorporate into the viral particle and yield higher titers on selected cancer cells.
rrVSV expressing Sindbis-SCA-erbb2 retained a small degree of infectivity against cells that did not express Her2/ neu indicating that not all of the native Sindbis binding function had been eliminated. Further work is necessary to disable this residual non-specific binding. Several investigators have identified areas of the E2 gp that may represent binding domains (Phinney et al., 2000; Smith et al., 1995; Zhang et al., 2002) . We have created an ideal means of testing the functional effects of mutations in these areas. We have a functional modified Sindbis E2 whose binding is in large part determined by an SCA. We can test whether a site is important for native Sindbis binding by mutating it and comparing infectivity in erbb2-positive and -negative cell lines. Without this capability, abolishing native binding would create a virus that could not be detected. One would have great difficulty distinguishing a mutation that selectively involved binding function from one that created a dysfunctional protein that did not traffic appropriately through the cell.
This study demonstrates the ability to easily create, directly from plasmid components, an oncolytic replicating adapting VSV with a restricted host cell range. We are testing this virus in the treatment of transplantable mouse tumors that express human her2/neu. The methodology and vector design allows easy substitution of genes expressing other SCA or binding proteins within the VSV genome to create rrVSV with a wide variety of specificities. VSV is an excellent candidate for development as an oncolytic virus because of its potency, safety and ability to be engineered.
Materials and methods

Cells, antibodies and chemicals
The following cell lines were obtained from American Type Culture Collection (ATCC) (Rockville, MD) and grown using standard tissue culture techniques in a humidified incubator at 37 8C with 5% CO 2 : SKBR3 human breast adenocarcinoma, 143 human osteosarcoma, COS-7 simian kidney and BHK 21 hamster kidney. SKBR3 cells are known Her2/neu amplified/over-expressing breast cancer cells whereas 143 do not express measurable Her2/ neu (Bergman et al., 2001) . D2F2/E2 is a mouse mammary tumor line that has been stably transfected with a vector expressing the human Her2/neu gene and was a generous gift from Dr. Wei-Zen Wei, Karmanos Cancer Institute, Wayne State University, Detroit, MI. D2F2 is the parent mouse mammary tumor cell line. Absence of mycoplasma contamination in all cell lines was confirmed by the Gen-Probe rapid detection system (Gen-Probe Incorp., San Diego, CA). MAb 4D5, a mouse monoclonal antibody directed to the Her2/neu receptor was provided by Genentech, Inc. (San Francisco, CA). Herceptin, the humanized form of 4D5 was obtained from Genentech. Bafilomycin A1 was obtained from Kamiya Biomedical Co. (Seattle, WA).
Flow cytometry
SKBR3 cells, 4 Â 10 5 /well, and 143 cells, 2 Â 10 5 /well, were plated simultaneously in individual wells of 6 well tissue culture trays (Corning Inc., Cat# 3516, Corning, NY). These cell numbers were chosen because we knew from previous experience that in 24 h, the wells would be nearly confluent with about equal numbers of adherent cells of the two cell lines. Cells were infected with rrVSV expressing Sindbis-SCA-erbb2 at MOI = 1 and harvested 8 h later. Cells were analyzed 8 h after infection before many infected cells expressed green fluorescence because at later times cell death interfered with interpretation of the assay. Flow cytometry was performed by incubating the cells with 100 Al of anti-erbb2 MAb 4D5 and then staining with a R-Phycoerythrinconjugated goat anti-mouse IgG antibody (Sigma P9670, St. Louis, MO). Immunofluorescence was quantified using a FACStarPlus cytometer (Becton Dickinson, Mountainview, CA). All cells were included in the analysis.
Vectors, VSV pseudotypes and recombinant VSV genomes
Vectors expressing the VSV genome (XN2) and the individual VSV genes P, L, N and G (pBS-P, L, N and G, respectively) on a T7 promoter were a very generous gift of Dr. John K. Rose, Yale University School of Medicine. A vector expressing VSV-G on a CMV promoter (CMV-VSV-G) was a generous gift of Dr. Paul D. Robbins, University of Pittsburgh School of Medicine. Vectors expressing Sindbis gp (Sindbis) and Sindbis gp modified between amino acids 71 and 74 to express two IgG binding domains (Sindbis-ZZ) were generously supplied by Dr. Irvin S. Y. Chen, University of California, Los Angeles Medical School. We replaced the ZZ IgG binding domain with a gene coding for an SCA to erbb2 as follows. A vector expressing an SCA based on the 4D5 anti-erbb2 antibody was a generous gift by Genentech Inc. The gene segment coding for the mature structural protein without the signal sequence was amplified with a series of primers to produce the following construct: ggtaacc(BstE II) agctcaggtggaggcggttcaggcggaggtggctctggcggtggcg gatctgctagc (Nhe 1)-mature SCA-erbB2atcgat(Cla 1) gctaaaacgaccgcaccgtcctgtctac ccactggcacctgtctcgtctggatccgggtctctggtaacc (BstE II). Preceding the mature SCA, between the BstEII and Nhe1 restriction sites we placed a flexible poly-glycine linker. Following the mature SCA between the Cla1 and BstEII restriction sites, we placed a spacer adapted from Jost et al. (1996) and consisting of the first 13 amino acids of the CH1 region of the 2C11 hamster monoclonal antibody and a flexible serine-glycine end. This construct now replaced ZZ between amino acids 71 and 74 of the Sindbis gp to create a chimeric Sindbis gp which consisted of the first 71 amino acids of E2 followed in order by a poly-glycine linker, SCA to erbb2, CH1 linker, the remainder of the E2 Sindbis gp and the entire E1 Sindbis gp. This construct was called Sindbis-SCA-erbb2. It was designed so that the specific SCA-erbb2 in this construct could easily be replaced with any other SCA by digesting and ligating at the Nhe1 and Cla1 sites.
The Sindbis-SCA-erbbB2 construct expressed through a CMV promoter was used to create VSV pseudotypes as previously described (Bergman et al., 2003) . In brief, we first constructed a recombinant VSV (rVSV) genome in which the G gene was replaced by a gene encoding green fluorescent protein (EGFP-DG/XN2). This construct was used to create a non-replicating virus whose genome consisted of rVSV-EGFP-DG and whose surface protein was G as follows (Lawson et al., 1995) . EGFP-DG/XN2, pBS-P, pBS-L, pBS-N, and pBS-G were transfected into COS-7 cells and infected at MOI = 6 with vTF-7, a vaccinia virus expressing T7 polymerase (NIH AIDS research and reference reagent program, Rockville, MD). Virus were harvested from the supernatant 2 days later and amplified on BHK 21 cells that were transfected with CMV-VSV-G using a standard lipofectamine protocol. Non-replicating pseudotype VSV were created by transfecting BHK 21 with DNA encoding either Sindbis gp or Sindbis-SCA-erbb2 gp and 2 days later infecting with rVSV-EGFP-DG at an MOI of 6. Supernatant was harvested 1 day following infection and stored at À70 8C. All pseudotype viruses, therefore, used in this report were made in BHK 21 cells. Titers were determined by adsorbing the virus at different dilutions on the indicator cell line in wells of a 6-well tray (Corning Inc.) for 2 h, washing and replacing the media. Green cells were counted in an inverted fluorescent microscope (Axiovert 135, Carl Zeiss, Inc., Thornwood, NY) 1 day later. Inhibition of viral titer by antibody to erbb2 was determined by incubating cells at 4 8C first with antibody for 30 min and then with virus and antibody for 60 min. This temperature was chosen to prevent antibody capping and endocytosis into the cell. The cells were then incubated overnight at 37 8C and the titer measured at 24h. The percent inhibition was 1 À (titer with antibody) / (titer without antibody) Â 100.
Similar techniques were used to create a recombinant replicating VSV whose surface gp was Sindbis-SCA-erbb2. First, the gene for Sindbis-SCA-erbb2 was digested from the vector supplied by Dr. Irvin S. Y. Chen and inserted into the recombinant VSV genome, EGFP-DG/XN2, between the genes for VSV-M and EGFP. This was accomplished by using primers to add a multiple cloning site containing Not1 and Pme1 restriction sites and VSV transcription stop and start signals (italics) in front of the gene for EGFP as follows: acgcgt (Mlu 1)cgtacggtaacctcgagaaagcggccgc (Not1)gcgcgtttaaac (Pme1) tatgaaaaaaactaacagagatccact. The Sindbis-SCA-erbb2 construct was then added between the Not1 and Pme1 restriction sites. In addition, for the purpose of our future in vivo studies, the gene for mouse GM-CSF was added at the Mlu 1 site by using primers to add an Mlu 1 site in front of the GM-CSF gene and stop and start signals followed by an Mlu 1 site at the end of the gene. This recombinant VSV genome was called mGMCSF-Sindbis-SCA-erbb2-EGFP-DG/XN2 (Fig. 9) . This new recombinant genome as well as pBS-P, pBS-L, pBS-N and pBS-G were transfected into COS-7 cells and infected with vTF-7. The pBS-G vector was included to make a virus that contained VSV-G on its surface and could be amplified on BHK 21 cells. Virus were harvested from the supernatant 2 days later and amplified on BHK 21 cells that were transfected with CMV-VSV-G, a vector that expresses wt VSV G protein. Viral stocks were made from virus grown in unmodified SKBR3 or D2F2/E2 cells and titered in the same cell lines. All replicating viruses used in this report were made in SKBR3 cells except the virus titered on D2F2/E2 which was grown on D2F2/E2. Viral RNA was harvested, converted to cDNA using RT-PCR and sequenced to prove that the gene for Sindbis-SCA-erbb2 was appropriately placed in the VSV genome. Because the gene for VSV G was deleted from the genome, the only surface gp on this virus was Sindbis-SCA-erbb2. Titers were determined as detailed above except that after 2 h of viral adsorption the media was replaced with media containing 30 nM Bafilomycin A1 to avoid counting newly produced virus.
Growth of replicating virus was determined by adsorbing the virus at MOI = 0.005 for 2 h on the indicator cell line, plated at 2 Â 10 5 cells in one well of a 6 well tray, washing three times, replacing the media and counting green cells in an inverted fluorescent microscope every 6 h for 24 h. The number of infected cells could not be accurately counted after this time because of cell clumping and lysis of early infected cells. Cytopathic effect (CPE) was determined by adsorbing the virus on the indicator cell line in one well of a 6-well tray at MOI = 10 for 2 h, washing, replacing the media and harvesting all cells after 1 day. The number of live cells in the virus infected well was divided by the number of live cells in a no virus control well and multiplied by 100 to determine the percentage of living cells following treatment. The percent CPE was 100 minus this number.
Analysis of the protein composition of pseudotype and replicating VSV and infected cells
Preparation of 35 S-labeled virus was performed as previously described with modifications (Whitaker- Dow-ling et al., 1983) . VSV pseudotypes were created by transfecting BHK 21 with DNA encoding either Sindbis gp or Sindbis-SCA-erbb2 gp. Twenty-four hours after transfection, the media was removed from each well and replaced with 1 ml of cysteine/methionine free media (Cat# 19050-121, Gibco/BRL,) containing 20 ACi/ml of 35 S-methionine (Trans35S-LABEL, 10 mCi/ml, ICN Biochemicals, Irvine, CA, Cat# 51006). Forty-eight hours after transfection, the cells were infected by the addition of VSV-EGFP-DG coated with G gp at a multiplicity of infection (MOI) of 5. After a 2-h adsorption period, the inoculum was removed and the cells refed with 1 ml of cysteine/methionine-free media containing 20 ACi/ml of 35 S-methionine. Seventy-two hours after transfection, the media containing the radiolabeled virus was harvested, and the cell debris removed by centrifugation at 1000 Â g for 5 min. The virus in the supernatant was then pelleted by ultracentrifugation in a swinging bucket rotor at 80,000 Â g for 2 h. The virus pellets were resuspended in 200 Al of complete medium and layered on a 10% to 40% sucrose gradient containing 10 mM Tris pH 7.4, 1 M NaCl, and 1 mM EDTA. The gradient was subjected to ultracentrifugation in a swinging bucket rotor at 35,000 Â g for 90 min. The radiolabeled viral band was collected and diluted to 33 ml with serum-free medium and repelleted by ultracentrifugation as described. The virus pellet was resuspended in 200 Al of serum-free medium. The purified radiolabeled virus was diluted 1:1 with 2Â Laemmli sample buffer and subjected to analysis by sodium dodecyl sulfate polyacrylamide gel electrophoresis using 10% acrylamide containing 0.09% bis acrylamide. The gel was dried under vacuum and examined by autoradiography. Viral bands were identified by their molecular weights. Viral yield following this extensive purification was low accounting, in part, for the inability to visualize the VSV P protein. Similar techniques were used to prepare 35 S-labeled recombinant replicating VSV whose surface gp was Sindbis-SCA-erbb2 or wt VSV G. Two hours after infection of SKBR3 cells in individual wells of a 6-well tissue culture tray (Corning Inc.) with either wt VSV or rrVSV at MOI = 6, the media was removed and replaced with 1 ml of cysteine/methionine free media containing 20 ACi/ml of 35 S-methionine. The media containing the radiolabeled virus was harvested 24 h after infection and the cell debris removed by centrifugation at 1000 Â g for 5 min. The virus in the supernatant was then pelleted and subjected to gel electrophoresis as above. Analysis of cellular proteins following viral infection was performed by infecting D2F2/E2 cells in individual wells of a 6 well tissue Fig. 9 . Gene structure in rrVSV expressing Sindbis-SCA-erbb2 (not drawn to scale). culture tray with rrVSV at MOI = 1. At various times, individual wells were labeled for 2 h with 35 S-methionine as above. The cell layer was then lysed in 2Â Laemmli sample buffer and subjected to gel electrophoresis.
